The Licensing of Medicines – Consequences of UK “Brexit Vote”

During our office opening event in Munich, Dr. David Jefferies (SVP at Eisai and chair at the EFPIA) had joined us to speak on the topic “The Licensing of Medicines – Consequences of UK “Brexit Vote”. The presentation found a lot of interest during the event, which is why we would like to share it with all our customers that are interested in this very current topic affecting the pharmaceutical industry worldwide.

To view the presentation please click the link below.